FDA greenlights first large-scale trial of gene-edited pig kidney transplants, signaling a turning point in xenotransplantation
In a milestone for transplant medicine, the US Food and Drug Administration has authorized the first large-scale clinical trial of genetically engineered pig kidney transplants. The move shifts xenotransplantation from one-off, compassionate-use procedures to a structured, multi-patient study designed to rigorously assess safety and effectiveness—an essential step toward easing the global organ shortage.
On September 8, Cambridge-based biotech company eGenesis announced Investigational New Drug approval for its EGEN-2784 pig kidney. The clearance enables a Phase 1/2/3 study that will evaluate safety, tolerability, and early efficacy over a 24-week period. Unlike earlier isolated surgeries, this trial will enroll multiple patients in parallel under a carefully controlled protocol, generating the kind of data regulators and clinicians need to confidently bring a new option to patients with end-stage renal disease.
The study is being led by a multidisciplinary team at Massachusetts General Hospital, including transplant specialist Leonardo V. Riella and surgeons Tatsuo Kawai and Nahel Elias. Industry collaborators such as Eledon, Apellis, and Karius are supporting the program, reflecting the complex interplay of surgery, immunology, and infectious disease monitoring required for cross-species organ transplantation.
Early patient results have been encouraging. Sixty-seven-year-old Tim Andrews has lived more than seven months without dialysis after receiving a gene-edited pig kidney in January 2025—longer than any previous recipient of a porcine organ. Another patient, fifty-four-year-old Bill Stewart, who received an EGEN-2784 kidney in June 2025, was discharged just one week post-surgery. While individual outcomes cannot substitute for a controlled trial, they underscore the tangible progress made in this emerging field.
A key differentiator for the EGEN-2784 program is its multi-layered genome engineering approach. The donor pigs are modified using three complementary strategies: removing antigens that trigger acute immune rejection, inserting select human genes to improve compatibility, and inactivating endogenous retroviruses to reduce the risk of viral transmission. According to eGenesis, it is currently the only organization implementing all three types of edits simultaneously in its porcine organs.
The urgency behind this research is clear. Only about 28,000 kidney transplants were performed in the United States in 2024, even as more than 800,000 Americans lived with severe kidney disease. For patients who remain on dialysis long-term, the five-year mortality rate exceeds 50%—worse than many cancers. Shortages and long waitlists are not limited to one country; they are a worldwide challenge with life-or-death consequences.
Xenotransplantation has a complicated history. Attempts with primate organs in the 1960s failed due to immediate rejection and infectious risks. Today’s convergence of gene editing, advanced immunosuppression, and meticulous clinical oversight marks a decisive break from that past. As eGenesis CEO Mike Curtis put it, this authorization represents a significant step toward overcoming the chronic scarcity of donor organs.
If the trial confirms the safety and effectiveness of EGEN-2784, it could open the door to a reliable, near-limitless supply of compatible kidneys for people with end-stage renal disease. Such a development would not replace traditional organ donation, but it could finally narrow the gap between the number of patients in need and the number of organs available—transforming outcomes for hundreds of thousands of people who depend on dialysis today.
For now, the focus turns to the data. Over the coming months, researchers will closely track how well these gene-edited pig kidneys function in human recipients, how the immune system responds, and how patients fare overall. The results could redefine what’s possible in transplant medicine and bring long-awaited hope to families waiting for a second chance at life.
